Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 600x60px
Document › Details

BIA Separations d.o.o.. (1/17/18). "Press Release: BIA Separations Appoints Pete Gagnon as Chief Scientific Officer". Ajdovšcina.

Organisations Organisation BIA Separations d.o.o.
  Group BIA Separations (Group)
  Organisation 2 Validated Biosystems
Products Product CIM® column (Convective Interaction Media monolithic chromatographic column)
  Product 2 chromatography
Persons Person Gagnon, Pete (BIA Separations 201801– CSO before Validated Biosystems)
  Person 2 Štrancar, Aleš (BIA Separations 201309 CEO + Chief Business Development Officer)
     


Appointment will drive new product and applications development


BIA Separations (BIA), a leading biochromatography development and manufacturing company, today announced it has appointed Pete Gagnon as Chief Scientific Officer. In his new role, he will drive the company’s new product and applications development, with a focus on the purification of products for gene therapy, oncolytic vaccines, exosomes and similar, and specifically increasing the safety of these products.

Previously President and CSO of Validated Biosystems, Gagnon assumes his new position with immediate effect. Gagnon has more than 30 years of experience in the biotech industry where he is widely respected for his work in the development of purification technology for the manufacture of biologics, including viruses and exosomes. The majority of his experience has been gained in the development of commercial purification procedures for recombinant human therapeutics. During his career, he has worked with all major chromatography suppliers, supporting the development of new products and applications in line with rapidly evolving industry needs.

Gagnon is the inventor of 20 granted patent families with 20 more pending, and has published more than 80 articles, cited in more than 700 scientific publications, addressing practical aspects of purifying biologics. He has authored a book titled Purification Tools for Monoclonal Antibodies, as well as being invited to contribute chapters to many other books, and sits on numerous scientific and editorial advisory boards.

Aleš Štrancar, CEO of BIA Separations, commented: “Pete’s scientific interests and experience are a perfect fit with our future development strategy and the stringent requirements associated with these classes of products. He has been an influential researcher and a user of BIA’s proprietary CIM® monolith technology for more than a decade, and his enthusiasm, practical skills and insights will make him an invaluable resource for our customers and partners, especially in the fast-developing and challenging fields of virus and exosome purification. This is an area where we expect to see new product lines emerging.”

Pete Gagnon, CSO of BIA Separations added: “I am sincerely delighted to join BIA where I look forward to highlighting the unique abilities of monoliths to elevate product quality, safety, and processing efficiency for some of the most challenging product classes in the field of human therapeutics. Process developers should anticipate the emergence of important and exciting first-in-the-field capabilities by mid-year, and continuing thereafter.”


ENDS


Pete Gagnon, CSO of BIA Separations
For a high-resolution image please contact Zyme Communications


Media contact

Sarah Jeffery
Zyme Communications
E: sarah.jeffery@zymecommunications.com
T: +44 (0)7771 730 919

At BIA Separations
Jana Krapež Trošt
Head of Marketing
E: marketing@monoliths.com
T: +386 (0)59 699 505


About BIA Separations www.biaseparations.com

BIA Separations is the leading developer and manufacturer of CIM® (Convective Interaction Media) monolithic chromatographic columns for production, purification, and analytics of large biomolecules. The company has research and production facilities in Slovenia, with sales offices and distributors throughout the world.

BIA Separations mission is to develop and produce CIM® monolithic columns of highest quality and provide superior research and method development services for purification and analytics of biomolecules. In addition the company aims to provide unique in-process control tools to better understand and control the bioprocesses.

   
Record changed: 2018-02-18

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for BIA Separations (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px